无码欧美成人av天堂456软件,大胆日本熟妇XXXX,9277在线观看免费播放,4p三个男人让我爽了一夜

產(chǎn)品訂購信息：
英文名稱  Anti-SPG3A/Atlastin 

中文名稱   G蛋白結(jié)合蛋白3抗體費(fèi)用 

別    名  AD FSP; atl1; ATLA1_HUMAN; Atlastin GTPase 1; Atlastin-1; Atlastin1; Brain specific GTP binding protein; Brain-specific GTP-binding protein; FSP1; GBP-3; GBP3; GTP-binding protein 3; Guanine nucleotide-binding protein 3; Guanylate binding protein 3; hGBP3; HSN1D; Spastic paraplegia 3 protein A; SPG 3A; SPG3; SPG3A.

濃    度   1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Rabbit 

產(chǎn)品類型   一抗  

研究領(lǐng)域    細(xì)胞生物 神經(jīng)生物學(xué) 結(jié)合蛋白 G蛋白偶聯(lián)受體 G蛋白信號(hào)

蛋白分子量  predicted molecular weight: 64kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human SPG3A/Atlastin (201-300aa) 

亞    型   IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

G蛋白結(jié)合蛋白3抗體費(fèi)用 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 Atlastins are Golgi-localized, integral membrane proteins that function as GTPases. The Atlastin proteins, also designated SPG3A and guanylate-binding protein 3, comprise a Dynamin superfamily that plays a role in axonal maintenance. Hereditary spastic paraplegia (HSP) is an inherited neurodegenerative disorder that is characterized by retrograde axonal degeneration. HSP primarily affects long corticospinal neurons and causes spastic lower extremity weakness. Spastin, a microtubule (MT)-severing AAA ATPase, is a binding partner of Atlastin that is involved in membrane dynamics. This Spastin/Atlastin binding may be involved in the biochemical pathway that leads to HSP development. Mutations in the Atlastin gene (SPG3A) account for approximately 10% of all autosomal dominant HSPs, while mutations in the Spastin gene (SPG4) account for almost 40%.

Function : GTPase tethering membranes through formation of trans-homooligomer and mediating homotypic fusion of endoplasmic reticulum membranes. Functions in endoplasmic reticulum tubular network biogenesis. May also regulate Golgi biogenesis. May regulate axonal development.

Subunit : Homooligomer. Interacts (via N-terminal region) withMAP4K4 (via CNH regulatory domain). Interacts with REEP5, RTN3 andRTN4 (via the transmembrane region). Interacts with SPAST;interaction is direct. May interact with TMED2. Interacts withREEP1.

Subcellular Location : Endoplasmic reticulum membrane. Golgi apparatus membrane. Cell projection > axon.

Tissue Specificity : Expressed predominantly in the adult and fetal central nervous system. Measurable expression in all tissues examined, although expression in adult brain is at least 50-fold higher than in other tissues. Detected predominantly in pyramidal neurons in the cerebral cortex and the hippocampus of the brain. Expressed in upper and lower motor neurons (at protein level).

DISEASE : Defects in ATL1 are the cause of spastic paraplegia autosomal dominant type 3 (SPG3) [MIM:182600]; also known as Strumpell-Lorrain syndrome. Spastic paraplegia is a degenerative spinal cord disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs.

Similarity : Belongs to the GBP family. Atlastin subfamily.

Database links : UniProtKB/Swiss-Prot: Q8WXF7.1

Anti-Phospho-TAK1 (Thr184/187)/FITC 熒光素標(biāo)記磷酸化轉(zhuǎn)化生長(zhǎng)因子β活化激酶1抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Insulin Receptor-Alpha(ISR-Alpha) 受體-α(抗原)Multi-class antibodies規(guī)格： 0.5mg

新型基因/一種新發(fā)現(xiàn)的基因抗體 Anti-Runx3 0.1ml

SHP-1 英文名稱： 造血細(xì)胞磷酸酶抗體 0.1ml

ECHS1 英文名稱： 烯脂酰輔酶A水解酶抗體 0.1ml

Rhesus antibody Rh phospho-MK1/MAP2K1(Thr292) 磷酸化原活化蛋白激酶1抗體 規(guī)格 0.1ml

Insulin Receptor-Alpha(ISR-Alpha) 受體-α(抗原)Multi-class antibodies規(guī)格： 0.5mg

Anti-phospho-P53 (Ser20)/FITC 熒光素標(biāo)記磷酸化抑制基因P53抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rabbit Anti-Goat IgG/Biotin 生物素化兔抗羊IgGMulti-class antibodies規(guī)格： 0.1ml

降鈣素抗體 Anti-CT 0.2ml

Rabbit Anti-mouse IgM/PE-CY5 PE-CY5標(biāo)記的兔抗小鼠IgM 0.1ml

FENS1 英文名稱： 磷酸肌醇結(jié)合蛋白1抗體 0.2ml

Rhesus antibody Rh phospho-YES1(Tyr537) 磷酸化原癌基因酪氨酸蛋白激酶Yes1抗體 規(guī)格 0.1ml

Rabbit Anti-Goat IgG/Biotin 生物素化兔抗羊IgGMulti-class antibodies規(guī)格： 0.1ml

IQGAP1 支架蛋白抗原Multi-class antibodies規(guī)格： 0.5mg

Anti-ADM R 腎上腺髓質(zhì)素受體抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh Phospho-cdc2 (Thr14) 磷酸化周期素依賴激酶2抗體 規(guī)格 0.1ml

BCIP/NBT顯色試劑盒-深藍(lán)色 50ml Sigma原料，單一組分

VAT1L 英文名稱： 囊泡胺轉(zhuǎn)運(yùn)蛋白1家族蛋白抗體 0.2ml

DRIL1 英文名稱： B淋巴細(xì)胞轉(zhuǎn)錄調(diào)節(jié)相關(guān)蛋白DRIL1抗體 0.2ml

Anti-ADM R 腎上腺髓質(zhì)素受體抗體Multi-class antibodies規(guī)格： 0.1ml

IL11RA Protein Canine 重組狗 IL11RA / IL-11RA / IL11Rα 蛋白 (His 標(biāo)簽)

大鼠視網(wǎng)膜色素上皮細(xì)胞完全培養(yǎng)基 100mL

KLK6 Others Human 人 KLK6 / Kallikrein 6 / Neurosin 人細(xì)胞裂解液 (陽性對(duì)照)

Tca-8113人舌鱗癌細(xì)胞 Tca-8113 human tongue squamous cell carcinoma 1640+10% FBS

人腦微內(nèi)皮細(xì)胞

NCI-H2452(人間皮瘤細(xì)胞) 5×106cells/瓶×2 L1210(細(xì)胞)

CM-R076大鼠主動(dòng)脈平滑肌細(xì)胞完全培養(yǎng)基100mL

ADCYAP1R1 Others Human 人 ADCYAP1R1 人細(xì)胞裂解液 (陽性對(duì)照)

小鼠皮膚肥大細(xì)胞完全培養(yǎng)基 100mL

SP2/0小鼠細(xì)胞 Mouse myeloma cell line SP2/0 RPMI-1640(GIBCO)+10%FBS

IL12B Protein Human 重組人 IL12B / P40 蛋白 (His 標(biāo)簽)

WI38/VA13(SV-40Z轉(zhuǎn)化) 5×106cells/瓶×2 3T3-L1, 小鼠前脂肪細(xì)胞

G蛋白結(jié)合蛋白3抗體費(fèi)用 IL11RA Protein Canine 重組狗 IL11RA / IL-11RA / IL11Rα 蛋白 (His 標(biāo)簽)

大鼠視網(wǎng)膜色素上皮細(xì)胞完全培養(yǎng)基 100mL

KLK6 Others Human 人 KLK6 / Kallikrein 6 / Neurosin 人細(xì)胞裂解液 (陽性對(duì)照)

Tca-8113人舌鱗癌細(xì)胞 Tca-8113 human tongue squamous cell carcinoma 1640+10% FBS

人腦微內(nèi)皮細(xì)胞

NCI-H2452(人間皮瘤細(xì)胞) 5×106cells/瓶×2 L1210(細(xì)胞)

抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：

1. G蛋白結(jié)合蛋白3抗體費(fèi)用 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定：

1）G蛋白結(jié)合蛋白3抗體費(fèi)用 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。